4 quarters tracked · Beat rate 100% · Updated quarterly
| Period | Report Date | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|---|
| Q1 2026 | 2026-03-31 | $1.95 | $2.03 | +4.0% | Beat |
| Q4 2025 | 2025-12-31 | $1.85 | $1.86 | +0.7% | Beat |
| Q3 2025 | 2025-09-30 | $2.17 | $2.47 | +13.7% | Beat |
| Q2 2025 | 2025-06-30 | $2.00 | $2.01 | +0.6% | Beat |
Earnings Beat Rate
Gilead Sciences has beaten analyst EPS estimates in 4 of 4 tracked quarters (100% beat rate). Data sourced from SEC filings and analyst consensus. View full AI analysis →